Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

A 3-hour WHO Hantavirus emergency Zoom call was held this morning, providing outbreak analysis. It seemed that for every ...

Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

Indian researchers accelerate pharma–nutraceutical integration to transform metabolic health: Nandita Vijayasimha, Bengaluru Tuesday, May 5, 2026, 08:00 Hrs [IST] India’s rese ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in ...